Anti-tumor necrosis factor-α in asthma [1]

American Journal of Respiratory and Critical Care Medicine

Volumn 175, Issue 3, 2007, Pages 288-

  Krouwels, Frans H ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; INFLIXIMAB; LONG ACTING DRUG; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ASTHMA; CLINICAL FEATURE; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; HEALTH PRACTITIONER; HUMAN; LETTER; MEDICAL INFORMATION; MORTALITY; PHYSICIAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 33846818653     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.175.3.288     Document Type: Letter

References (4)

1. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med 2006;174:753-762.
2. National Institutes of Health; National Heart, Lung, and Blood Institute. Global Initiative for Asthma (GINA): global strategy for asthma management and prevention. Available from: www.ginasthma.com (updated 2005).
3. Keane J, Gershon SK, Braun MM. Tuberculosis and treatment with infliximab. N Engl J Med 2002;346:625-626.
4. British Thoracic Society Standards of Care Committee. BTS recommendation for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNFα treatment. Thorax 2005;60:800-805.